CGRPR (calcitonin gene-related peptide receptor) antagonists are a class of pharmaceuticals used in the treatment of CGRP-related disorders, primarily migraines, and cluster headaches. These antagonists work by blocking the activity of the CGRP receptor, thereby inhibiting the transmission of pain signals associated with these conditions. According to WHO, migraines affect approximately 15% of the population in Europe and the USA, with women being three times more likely to be affected than men. Migraine attacks can cause severe pain, lasting from a few hours to several days, and can significantly impact daily functioning. Cluster headaches, though less common, are known for their excruciating intensity, with attacks often occurring in clusters over weeks or months. The market for CGRPR antagonists is driven by the growing prevalence of migraines and cluster headaches. According to the American Migraine Foundation, migraines alone result in an estimated $36 billion in annual healthcare costs and lost productivity in the USA. Additionally, the development and approval of novel CGRPR antagonists, such as Aimovig (erenumab), Emgality (galcanezumab), and Ajovy (fremanezumab), have expanded treatment options for patients and contributed to market growth.
The increasing recognition of CGRP-related disorders, advancements in research, and the potential for CGRPR antagonists to address unmet medical needs further contribute to market expansion. Companies such as Pfizer, Merck (MSD), AbbVie, Teva, AffaMed Therapy, Amgen, BMS, Boehringer Ingelheim, and Daiichi Sankyo are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, MSD is currently conducting a clinical trial of the drug MK-3207 for the treatment of headaches.
Key Developments
- In June 2023, Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion of Atogepant for migraine in the European union.
- In Nov 2022, Otsuka Pharmaceutical launched an autoinjector dosage form for Fremanezumab subcutaneous injection 225mg for the prevention of Migraine in Japan
Approved CGRPR Antagonists molecules
- Aimovig (erenumab-aooe)
- Ajovy (fremanezumab)
- Emgality (galcanezumab)
- Nurtec ODT (rimegepant ODT)
- Vyepti (eptinezumab)
CGRPR Antagonists Pipeline Molecules
- telcagepant (MK-0974)
- rimegepant (BHV-3000)
- MK-3207
- zavegepant oral (BHV-3500 oral)
- BHV-3100
- UB-313
Clinical Activity and Development of CGRPR Antagonists
In the CGRPR Antagonists space, there are very few companies, conducting more than more than 100 clinical trials in this category of drugs. For instance,
- In June 2023, AbbVie initiated enrolment in a phase I pharmacokinetic trial of Atogepant
- In June 2023, Teva Pharmaceutical released updated pooled efficacy data from phase III FOCUS and HALO trials Ajovy in Migraine
|
Product Name |
Total Studies |
|
Telcagepant (MK-0974) |
22 |
|
Rimegepant (BHV-3000) |
7 |
|
MK-3207 |
3 |
|
Zavegepant oral (BHV-3500 oral) |
2 |
Target Indication Analysis of CGRPR Antagonists
CGRPR (calcitonin gene-related peptide receptor) antagonists are a class of pharmaceuticals designed to target CGRP-related disorders, primarily migraines and cluster headaches. These antagonists work by blocking the activity of the CGRP receptor, thereby inhibiting the transmission of pain signals associated with these conditions. By effectively reducing the frequency and severity of migraine attacks, CGRPR antagonists offer a promising therapeutic option for individuals who experience debilitating headaches. Ongoing research is exploring their potential in other indications such as post-traumatic headache, trigeminal neuralgia, and chronic pain syndromes, expanding their potential impact in improving the quality of life for patients suffering from CGRP-mediated disorders.
Regional Analysis of CGRPR Antagonists
CGRPR Antagonists Market
The global CGRPR Antagonists market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US market for CGRPR antagonists shows significant potential for growth. The high prevalence of migraine and cluster headache patients in the country, coupled with the increasing awareness and diagnosis of CGRP-related disorders, contributes to market expansion. Additionally, the availability of innovative CGRPR antagonist medications, such as Aimovig, Emgality, and Ajovy, provides treatment options for patients who have not responded well to traditional therapies. Furthermore, the presence of robust healthcare infrastructure, favorable reimbursement policies, and strong market competition among pharmaceutical companies drive the adoption and market penetration of CGRPR antagonists in the US. These factors, combined with ongoing research and development efforts, are expected to fuel continued growth in the US CGRPR antagonist market. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for CGRPR Antagonists. These countries are increasingly adopting CGRPR Antagonists due to their efficacy and potential to improve patient outcomes. On the other hand, the CGRPR Antagonists market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the CGRPR Antagonists market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
CGRPR Antagonists drugs are used in the management of migraines and cluster headaches.
The increasing recognition of CGRP-related disorders, advancements in research, and the potential for CGRPR antagonists to address unmet medical needs further contribute to market expansion.
The major players in this space are Pfizer, Merck (MSD), AbbVie, Teva, AffaMed Therap, Amgen, BMS, Boehringer Ingelheim, and Daiichi Sankyo are pharmaceutical companies operating in the healthcare industry.
One of the restraints of the CGRPR (calcitonin gene-related peptide receptor) antagonist market is the limited awareness and understanding of CGRP-related disorders among healthcare professionals, leading to underdiagnosis and underutilization of CGRPR antagonists. Additionally, the high cost of CGRPR antagonist medications can pose a barrier to access for some patients, limiting their adoption and market growth.
- Pfizer
- Merck (MSD)
- AbbVie
- Teva
- AffaMed Therap
- Amgen
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Eli Lilly
- Lundbeck
- Novartis
- Otsuka
- Sosei
- Vaxxinity